1.

Record Nr.

UNINA9910253944103321

Titolo

In Vivo Reprogramming in Regenerative Medicine / / edited by Açelya Yilmazer

Pubbl/distr/stampa

Cham : , : Springer International Publishing : , : Imprint : Humana, , 2017

ISBN

3-319-65720-8

Edizione

[1st ed. 2017.]

Descrizione fisica

1 online resource (XVII, 103 p. 15 illus. in color.)

Collana

Stem Cell Biology and Regenerative Medicine, , 2196-8985

Disciplina

612.028

571.538

Soggetti

Regenerative medicine

Tissue engineering

Stem cells

Cell culture

Surgical transplantation

Regenerative Medicine/Tissue Engineering

Stem Cells

Cell Culture

Transplant Surgery

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Nota di contenuto

Chapter 1. Introduction to in vivo cell Reprogramming Technology -- Chapter 2. In vivo Reprogramming for Regenerating Insulin-Secreting Cells -- Chapter 3. Direct Reprogramming to Beta Cells -- Chapter 4. In vivo Lineage Reprogramming of Fibroblasts to Cardiomyocytes for Heart Regeneration -- Chapter 5: In vivo cell Reprogramming for Long-term Pluripotency -- Chapter 6: In vivo Transient Reprogramming Towards Pluripotency for Tissue Repair and Regeneration -- Chapter 7. Challenges and Future Perspectives for in vivo Reprogramming Technology.

Sommario/riassunto

There have been significant improvements in the development of cell based therapies; however, current treatment strategies still suffer from some problems: the need for long in vitro culture conditions, inefficient



delivery of cells by scaffolds and low incorporation and grafting efficiencies. Therefore, in vivo reprogramming has emerged as a novel treatment technology. In the process of in vivo reprogramming, cells switch to another cell type within the living organism. Leaders in the field discuss how in vivo reprogramming can be used for tissue repair and regeneration in different organs, including pancreas, liver and heart. Furthermore, recent studies on in vivo cell reprogramming towards pluripotency are also reviewed. Current challenges of these preclinical studies are discussed and hypothesis and suggestions are given in order to improve the current strategies to achieve translation into clinic. .